《华盛顿邮报》：没有冠状病毒的岛国帕劳很快就会为几乎所有人民接种疫苗
人口接近 18,000 人的小岛国帕劳已成功摆脱了 COVID-19 疾病的困扰。作为与美国“自由联合”协议的一部分，帕劳可以获得 Moderna COVID-19 疫苗，并计划到 2021 年 4 月实现几乎所有人口的免疫。
要了解更多信息，请点击以下链接：
《华盛顿邮报》：没有冠状病毒的岛国帕劳很快就会为几乎所有人民接种疫苗
时代报：我们不能推迟疫苗的推出，冒着冬季患重大疾病的风险
许多科学家呼吁暂停拟议中的 COVID-19 疫苗推广，这是一个令人担忧的问题。
The following article suggests that Australia's initial public health goal should be a rapid vaccine rollout and not herd immunity, in order to limit further risk of major illness. In order to achieve a rapid rollout, both the AstraZeneca and Pfizer COVID-19 vaccines are needed. Recent modelling suggests that vaccination will most likely shift SARS-CoV-2 from a virus causing major disease burden, to a relatively benign coronavirus causing the common cold.
要完整阅读文章，请点击以下链接：
高峰机构支持澳大利亚的 COVID-19 疫苗战略
在 2020 年 1 月 13 日发布的声明中， 澳大利亚传染病协会 (ASID)， 这 澳大利亚感染预防与控制学院 (ACIPC) 和 澳大利亚公共卫生协会 (PHAA) have shown support for the Commonwealth Government's COVID-19 vaccine strategy. The statement suggests that recent media reports surrounding concerns for the ability of any vaccine to create herd immunity is unjustified and reinforces that the public should have confidence in the approach being taken to provide COVID-19 vaccines to Australians.
要完整阅读该声明，请点击以下链接：
Zostavax vaccine: Safety advisory - risk of disseminated varicella zoster virus (vaccine strain) infection
Following a third report of fatal disseminated vaccine strain varicella-zoster virus infection following Zostavax administration, the Therapeutic Goods Administration (TGA) is reminding health professionals that Zostavax should not be used in people with compromised immune function.
Further details on the alert can be seen here:
Zostavax vaccine: Safety advisory
For more information on Zostavax® and access to the Zostavax® GP decision aid please review the MVEC pages below:
微血管内皮细胞： 带状疱疹
微血管内皮细胞： Zoster vaccine (Zostavax®) FAQ’s
FDA report reveals phase 3 clinical trial data for the Moderna COVID-19 vaccine candidate
In preparation for a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC), the FDA has made public the interim results of phase 3 clinical trials for the Moderna COVID-19 vaccine candidate. This meeting will discuss the Emergency Use Authorisation (EUA) application and determine any recommendations for approval.
Phase 3 clinical trials for this vaccine were spread across 99 sites in the United States and participants were aged 18 years or older. The Moderna vaccine utilises a messenger RNA (mRNA) platform. Interim results show an acceptable safety profile. Following the administration of 2 doses, 28 days apart, it is reported that this vaccine has an efficacy rate of 94.5%.
To read the document in full please refer to the link below:
对话：昆士兰大学/CSL 疫苗为何因 HIV 检测“假阳性”而失败？疫苗专家解释
Further clinical trials of the UQ/CSL COVID-19 vaccine candidate have been called off after phase 1 results showed that participants had returned 'false positive' HIV tests. The UQ/CSL vaccine utilises molecular clamp technology involving components of a HIV protein. These components are unable to cause a HIV infection, however participants were shown to be creating antibodies against HIV which then leads to a false positive HIV test result.
以下文章证实未发现任何安全问题。它表明研究人员采取了适当行动，以减少对不准确测试结果的不必要焦虑，并增强公众对未来 COVID-19 疫苗计划的信心。
要阅读全文，请点击以下链接：
对话：昆士兰大学/CSL 疫苗为何因 HIV 检测“假阳性”而失败？疫苗专家解释
The Conversation: People with severe allergies warned off Pfizer COVID vaccine for now. But that may change as more details emerge
As a precautionary measure, the UK medicines regulator have advised that people with a significant history of allergic reactions should not receive the Pfizer/BioNTech COVID-19 vaccine after 2 people experienced allergic reactions. The following article outlines how common allergies to vaccines are, why these types of reactions weren't noted in clinical trials and the role of ongoing safety surveillance and monitoring.
要阅读全文，请点击以下链接：
Australian Government Department of Health: COVID-19 vaccines
The Australian Government Department of Health have developed a dedicated resource for COVID-19 vaccines. This site will host news and information for Australians about the development, approval process and plans for COVID-19 vaccines.
To access this resource, please follow the link below:
Australian Government Department of Health: COVID-19 vaccines
FDA report reveals phase 3 clinical trial data for the Pfizer and BioNTech COVID-19 vaccine candidate
In preparation for a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC), the FDA has made public the interim results of phase 3 clinical trials for the Pfizer and BioNTech COVID-19 vaccine candidate. This meeting will discuss the Emergency Use Authorisation (EUA) application and determine any recommendations for approval.
Phase 3 clinical trials were spread across the US, Argentina, Brazil, Germany, South Africa and Turkey. The Pfizer and BioNTech vaccine candidate utilises a messenger RNA (mRNA) platform and its' studies involved participants aged 16 to 85 years. Findings have shown that the vaccine candidate has an acceptable safety profile and following the administration of 2 doses, has an efficacy rate of 95%.
To read the document in full please refer to the link below: